Literature DB >> 3098256

A calculator program for determining indices of neonatal respiratory distress syndrome severity.

J D Horbar.   

Abstract

The potential for treating and preventing neonatal respiratory distress syndrome (RDS) with exogenous surfactant has created renewed interest in quantitative measures and derived scores that can be used to assess disease severity. Many different indices of RDS severity have been suggested. They are useful as outcome measures in clinical trials and may assist in the early identification of infants at risk for severe complications. In this article, a program for the Hewlett-Packard 41CV programmable calculator is presented that calculates indices of RDS severity based on ventilator settings and arterial blood gas values.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3098256     DOI: 10.1055/s-2007-999731

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  4 in total

1.  A comparison of indices of respiratory failure in ventilated preterm infants.

Authors:  N V Subhedar; A T Tan; E M Sweeney; N J Shaw
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-09       Impact factor: 5.747

2.  A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome.

Authors:  J D Horbar; R F Soll; H Schachinger; G Kewitz; H T Versmold; W Lindner; G Duc; D Mieth; O Linderkamp; E P Zilow
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

3.  Prediction of respiratory failure in late-preterm infants with respiratory distress at birth.

Authors:  Gabriel Dimitriou; Sotirios Fouzas; Ioannis Giannakopoulos; Vassilis G Papadopoulos; George Decavalas; Stefanos Mantagos
Journal:  Eur J Pediatr       Date:  2010-07-29       Impact factor: 3.183

4.  Surfactant without Endotracheal Tube Intubation (SurE) versus Intubation-Surfactant-Extubation (InSurE) in Neonatal Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Lirong Wang; Min Zhang; Qingfeng Yi
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-16       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.